Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Filings indexed 296 across all filing types
Latest filing 2026-05-15 Annual Report
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 85% confidence The document is a Korean “사업보고서” (Business Report), which is the statutory annual report filed by the company. Although this filing is labelled as a correction (“정정신고”) to the originally submitted business report, the text includes the full detailed content of the corrected sections (company overview, business segments, products/services, sales breakdown, R&D agreements, etc.). This is not a mere notice pointing to a report (RPA) but the actual corrected annual report content. Therefore, it should be classified as an Annual Report (10-K). FY 2025
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is titled “분기보고서” for the 61st fiscal period covering 2026-01-01 to 2026-03-31. It is a comprehensive quarterly report filed with the Financial Services Commission and the Korea Exchange, containing detailed company overview, segment information, capital changes, and substantive financial data. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a ‘주식등의 대량보유상황보고서’ (Report on Large Shareholding Positions) containing detailed disclosures on shareholding levels, threshold crossings, and changes by major shareholders and their related parties. This matches the definition of a Major Shareholding Notification. There is no indication it is an AGM material, earnings release, management discussion, or proxy. Hence, classification as MRQ is appropriate.
2026-05-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 91% confidence The document is a Korean “임원ㆍ주요주주 특정증권등 소유상황보고서,” detailing an executive’s and major shareholder’s holdings and changes in specific securities, including share acquisitions and conversions. This is a regulatory insider transaction report by a director/executive, matching the definition of Director’s Dealing (insider trades).
2026-05-12 Korean
전환청구권ㆍ신주인수권ㆍ교환청구권행사
Share Issue/Capital Change Classification · 95% confidence The document is a corporate disclosure detailing the exercise of conversion rights on convertible bonds, resulting in the issuance of new shares (699,863 shares, 3.18% of total). It is announcing a change in the company’s capital structure via a share issuance. This falls squarely under Share Issue/Capital Change (SHA), not a repurchase or broader financing update.
2026-05-12 Welsh
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 90% confidence The document is a Korean “최대주주등소유주식변동신고서” (report of changes in major shareholder ownership), listing before/after shareholdings for the company’s largest shareholders and executives. It is a notification of significant share ownership changes, matching the Major Shareholding Notification category.
2026-05-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.